1. Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. Neuro Oncol. 2020;22(12 Suppl 2):iv1-iv96.
2. Bastola S, Pavlyukov MS, Yamashita D, Ghosh S, Cho H, Kagaya N, et al. Glioma-initiating cells at tumor edge gain signals from tumor core cells to promote their malignancy. Nat Commun. 2020;11(1):4660.
3. Nabors LB, Portnow J, Ahluwalia M, Baehring J, Brem H, Brem S, et al. Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18(11):1537-70.
4. Xu S, Tang L, Li X, Fan F, Liu Z. Immunotherapy for glioma: Current management and future application. Cancer Lett. 2020;476:1-12.
5. Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. Jama. 2017;318(23):2306-16.
6. McGranahan T, Therkelsen KE, Ahmad S, Nagpal S. Current State of Immunotherapy for Treatment of Glioblastoma. Curr Treat Options Oncol. 2019;20(3):24.
7. Sharma MC. Annexin A2 (ANX A2): An emerging biomarker and potential therapeutic target for aggressive cancers. Int J Cancer. 2019;144(9):2074-81.
8. Gerke V, Moss SE. Annexins: from structure to function. Physiol Rev. 2002;82(2):331-71.
9. Hajjar KA, Krishnan S. Annexin II: a mediator of the plasmin/plasminogen activator system. Trends Cardiovasc Med. 1999;9(5):128-38.
10. Wang CY, Lin CF. Annexin A2: its molecular regulation and cellular expression in cancer development. Dis Markers. 2014;2014:308976.
11. Mussunoor S, Murray GI. The role of annexins in tumour development and progression. J Pathol. 2008;216(2):131-40.
12. Wang T, Wang Z, Niu R, Wang L. Crucial role of Anxa2 in cancer progression: highlights on its novel regulatory mechanism. Cancer Biol Med. 2019;16(4):671-87.
13. Dallacasagrande V, Hajjar KA. Annexin A2 in Inflammation and Host Defense. Cells. 2020;9(6).
14. Christensen MV, Høgdall CK, Jochumsen KM, Høgdall EVS. Annexin A2 and cancer: A systematic review. Int J Oncol. 2018;52(1):5-18.
15. Pouliquen DL, Boissard A, Coqueret O, Guette C. Biomarkers of tumor invasiveness in proteomics (Review). Int J Oncol. 2020;57(2):409-32.
16. Chen CY, Lin YS, Chen CH, Chen YJ. Annexin A2-mediated cancer progression and therapeutic resistance in nasopharyngeal carcinoma. J Biomed Sci. 2018;25(1):30.
17. Horbinski C. What do we know about IDH1/2 mutations so far, and how do we use it? Acta Neuropathol. 2013;125(5):621-36.
18. Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, et al. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res. 2009;11(2):R15.
19. Li S, Zou H, Shao YY, Mei Y, Cheng Y, Hu DL, et al. Pseudogenes of annexin A2, novel prognosis biomarkers for diffuse gliomas. Oncotarget. 2017;8(63):106962-75.
20. Gao H, Yu B, Yan Y, Shen J, Zhao S, Zhu J, et al. Correlation of expression levels of ANXA2, PGAM1, and CALR with glioma grade and prognosis. J Neurosurg. 2013;118(4):846-53.
21. Kim DM, Noh HB, Park DS, Ryu SH, Koo JS, Shim YB. Immunosensors for detection of Annexin II and MUC5AC for early diagnosis of lung cancer. Biosens Bioelectron. 2009;25(2):456-62.
22. Ji NY, Park MY, Kang YH, Lee CI, Kim DG, Yeom YI, et al. Evaluation of annexin II as a potential serum marker for hepatocellular carcinoma using a developed sandwich ELISA method. Int J Mol Med. 2009;24(6):765-71.
23. Cua S, Tan HL, Fong WJ, Chin A, Lau A, Ding V, et al. Targeting of embryonic annexin A2 expressed on ovarian and breast cancer by the novel monoclonal antibody 2448. Oncotarget. 2018;9(17):13206-21.
24. Lokman NA, Ween MP, Oehler MK, Ricciardelli C. The role of annexin A2 in tumorigenesis and cancer progression. Cancer Microenviron. 2011;4(2):199-208.
25. Sharma M, Blackman MR, Sharma MC. Antibody-directed neutralization of annexin II (ANX II) inhibits neoangiogenesis and human breast tumor growth in a xenograft model. Exp Mol Pathol. 2012;92(1):175-84.
26. Bharadwaj A, Bydoun M, Holloway R, Waisman D. Annexin A2 heterotetramer: structure and function. Int J Mol Sci. 2013;14(3):6259-305.
27. Kumari S, Malla R. New Insight on the Role of Plasminogen Receptor in Cancer Progression. Cancer Growth Metastasis. 2015;8:35-42.
28. Ling Q, Jacovina AT, Deora A, Febbraio M, Simantov R, Silverstein RL, et al. Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J Clin Invest. 2004;113(1):38-48.
29. Luo M, Hajjar KA. Annexin A2 system in human biology: cell surface and beyond. Semin Thromb Hemost. 2013;39(4):338-46.
30. O'Connell PA, Surette AP, Liwski RS, Svenningsson P, Waisman DM. S100A10 regulates plasminogen-dependent macrophage invasion. Blood. 2010;116(7):1136-46.
31. Maire CL, Mohme M, Bockmayr M, Fita KD, Riecken K, Börnigen D, et al. Glioma escape signature and clonal development under immune pressure. J Clin Invest. 2020;130(10):5257-71.
32. Aarli A, Skeie Jensen T, Kristoffersen EK, Bakke A, Ulvestad E. Inhibition of phytohaemagglutinin-induced lymphoproliferation by soluble annexin II in sera from patients with renal cell carcinoma. Apmis. 1997;105(9):699-704.
33. Qiu LW, Liu YF, Cao XQ, Wang Y, Cui XH, Ye X, et al. Annexin A2 promotion of hepatocellular carcinoma tumorigenesis via the immune microenvironment. World J Gastroenterol. 2020;26(18):2126-37.
34. Loef EJ, Brooks AES, Lorenz N, Birch NP, Dunbar PR. Neuroserpin regulates human T cell-T cell interactions and proliferation through inhibition of tissue plasminogen activator. J Leukoc Biol. 2020;107(1):145-58.
35. Sharma MC, Tuszynski GP, Blackman MR, Sharma M. Long-term efficacy and downstream mechanism of anti-annexinA2 monoclonal antibody (anti-ANX A2 mAb) in a pre-clinical model of aggressive human breast cancer. Cancer Lett. 2016;373(1):27-35.
36. Leong L, Tan HL, Cua S, Yong KSM, Chen Q, Choo A. Preclinical Activity of Embryonic Annexin A2-Specific Chimeric Antigen Receptor T Cells Against Ovarian Cancer. Int J Mol Sci. 2020;21(2).
37. Kim VM, Blair AB, Lauer P, Foley K, Che X, Soares K, et al. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies. J Immunother Cancer. 2019;7(1):132.
38. Tan HL, Tan BZ, Goh WXT, Cua S, Choo A. In vivo surveillance and elimination of teratoma-forming human embryonic stem cells with monoclonal antibody 2448 targeting annexin A2. Biotechnol Bioeng. 2019;116(11):2996-3005.
39. Marlin R, Pappalardo A, Kaminski H, Willcox CR, Pitard V, Netzer S, et al. Sensing of cell stress by human γδ TCR-dependent recognition of annexin A2. Proc Natl Acad Sci U S A. 2017;114(12):3163-8.
40. Andersen BM, Xia J, Epstein AL, Ohlfest JR, Chen W, Blazar BR, et al. Monomeric annexin A2 is an oxygen-regulated toll-like receptor 2 ligand and adjuvant. J Immunother Cancer. 2016;4:11.
41. Maule F, Bresolin S, Rampazzo E, Boso D, Della Puppa A, Esposito G, et al. Annexin 2A sustains glioblastoma cell dissemination and proliferation. Oncotarget. 2016;7(34):54632-49.